The role of arginine vasopressin and its receptors in the normal and failing rat heart

被引:30
作者
Chandrashekhar, Y [1 ]
Prahash, AJ [1 ]
Sen, S [1 ]
Gupta, S [1 ]
Roy, S [1 ]
Anand, IS [1 ]
机构
[1] Univ Minnesota, Div Cardiol, VA Med Ctr, Minneapolis, MN 55425 USA
关键词
AVP; heart failure; ventricular remodeling; cardiomyocytes; receptors;
D O I
10.1016/S0022-2828(03)00053-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - To evaluate the role of arginine vasopressin (AVP) in the normal and post-myocardial infarction (post-MI) hearts, and to investigate whether chronic AVP receptor antagonism can attenuate post-infarct ventricular remodeling. Background - A number of neurohormones, like norepinephrine and angiotensin II, have detrimental effects in heart failure (HF) and inhibiting them is beneficial. AVP shares some important properties with these hormones and is activated in HF. However, its role in the syndrome of HF, especially the effect of AVP inhibition, is largely undefined. Methods and results - Effects of AVP-V1(a) and AVP-V-2 receptor stimulation on normal rat cardiomyocyte contractile function, intracellular calcium [Ca2+](i), inositol 3 phosphate (IP3) generation and cell survival were studied. In post-MI rats, AVP receptor function was assessed in cardiomyocytes as well as isolated working hearts. AVP receptor total number (ligand binding) and mRNA levels (RT-PCR) were measured in myocytes. Finally, the effects of chronic AVP-V1(a) blockade were assessed in post-MI rats using echo and morphometry to measure ventricular remodeling. Normal cardiomyocytes showed a dose-dependent increase in myocyte contractile function, [Ca2+](i), and IP3 generation in response to AVP-V1(a) receptor stimulation. AVP-V-2 agonists had no effect. Cells from MI hearts showed reduced inotropic response to AVP-V1(a) stimulation. Myocyte AVP-V1(a) receptor number and receptor mRNA were decreased. Prolonged exposure to AVP reduced cellular viability. However, chronic AVP-V1(a) blockade did not attenuate structural remodeling or improve function in post-MI hearts. Conclusions - Isolated adult rat cardiomyocytes bear AVP-V1(a), receptors that mediate inotropic effects through the IP3 pathway. These receptors are functionally and numerically downregulated in the post-MI remodeled hearts. Despite evidence that AVP is cytotoxic to cells, chronic AVP-V1(a) receptor blockade does not attenuate post-MI ventricular remodeling in this model. Thus, AVP may not play a major role in the structural progression of HF. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:495 / 504
页数:10
相关论文
共 30 条
[11]   Evidence for a vasopressin system in the rat heart [J].
Hupf, H ;
Grimm, D ;
Riegger, GAJ ;
Schunkert, H .
CIRCULATION RESEARCH, 1999, 84 (03) :365-370
[12]  
LASZLO FA, 1991, PHARMACOL REV, V43, P73
[13]   ADRENERGIC EFFECTS ON THE BIOLOGY OF THE ADULT MAMMALIAN CARDIOCYTE [J].
MANN, DL ;
KENT, RL ;
PARSONS, B ;
COOPER, G .
CIRCULATION, 1992, 85 (02) :790-804
[14]  
MAOLIC JM, 1989, J HYPERTENS, V7, P195
[15]  
MATSUI H, 1992, HYPERTENSION, V9, P730
[16]   CORONARY VASOCONSTRICTION INDUCED BY VASOPRESSIN - PRODUCTION OF MYOCARDIAL-ISCHEMIA IN DOGS BY CONSTRICTION OF NONDISEASED SMALL VESSELS [J].
MATURI, MF ;
MARTIN, SE ;
MARKLE, D ;
MAXWELL, M ;
BURRUSS, CR ;
SPEIR, E ;
GREENE, R ;
RO, YM ;
VITALE, D ;
GREEN, MV ;
GOLDSTEIN, SR ;
BACHARACH, SL ;
PATTERSON, RE .
CIRCULATION, 1991, 83 (06) :2111-2121
[17]   EFFECTS OF A VASOPRESSIN ANTAGONIST WITH COMBINED ANTIPRESSOR AND ANTIANTIDIURETIC ACTIVITIES IN RATS WITH LEFT-VENTRICULAR DYSFUNCTION [J].
MULINARI, RA ;
GAVRAS, I ;
WANG, YX ;
FRANCO, R ;
GAVRAS, H .
CIRCULATION, 1990, 81 (01) :308-311
[18]   EFFECTS OF ORAL AVP RECEPTOR ANTAGONISTS OPC-21268 AND OPC-31260 ON CONGESTIVE-HEART-FAILURE IN CONSCIOUS DOGS [J].
NAITOH, M ;
SUZUKI, H ;
MURAKAMI, M ;
MATSUMOTO, A ;
ARAKAWA, K ;
ICHIHARA, A ;
NAKAMOTO, H ;
OKA, K ;
YAMAMURA, Y ;
SARUTA, T .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1994, 267 (06) :H2245-H2254
[19]   Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats [J].
Nishikimi, T ;
Kawano, Y ;
Saito, Y ;
Matsuoka, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (02) :275-282
[20]  
OKUDA H, 1994, AM J PHYSIOL, V267, pR1467